SI20191A - Priprave za administracijo zdravil ter metode za zdravljenje virusnih in mikrobnih infekcij in sindroma hiranja - Google Patents

Priprave za administracijo zdravil ter metode za zdravljenje virusnih in mikrobnih infekcij in sindroma hiranja Download PDF

Info

Publication number
SI20191A
SI20191A SI9820040A SI9820040A SI20191A SI 20191 A SI20191 A SI 20191A SI 9820040 A SI9820040 A SI 9820040A SI 9820040 A SI9820040 A SI 9820040A SI 20191 A SI20191 A SI 20191A
Authority
SI
Slovenia
Prior art keywords
dmf
administration
treatment
alkyl groups
methyl
Prior art date
Application number
SI9820040A
Other languages
English (en)
Slovenian (sl)
Inventor
Michelle Olga Patricia Giesteira Visser
Original Assignee
Cryopreservation Technologies Cc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/874,425 external-priority patent/US5935597A/en
Application filed by Cryopreservation Technologies Cc filed Critical Cryopreservation Technologies Cc
Publication of SI20191A publication Critical patent/SI20191A/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medical Informatics (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
SI9820040A 1997-06-13 1998-06-09 Priprave za administracijo zdravil ter metode za zdravljenje virusnih in mikrobnih infekcij in sindroma hiranja SI20191A (sl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/874,425 US5935597A (en) 1995-12-15 1997-06-13 Drug delivery devices and methods for treatment of viral and microbial infections and wasting syndromes
PCT/US1998/011956 WO1998056325A1 (en) 1997-06-13 1998-06-09 Drug delivery devices and methods for treatment of viral and microbial infections and wasting syndromes

Publications (1)

Publication Number Publication Date
SI20191A true SI20191A (sl) 2000-10-31

Family

ID=25363728

Family Applications (1)

Application Number Title Priority Date Filing Date
SI9820040A SI20191A (sl) 1997-06-13 1998-06-09 Priprave za administracijo zdravil ter metode za zdravljenje virusnih in mikrobnih infekcij in sindroma hiranja

Country Status (34)

Country Link
EP (1) EP1011567A1 (lt)
JP (1) JP4531141B2 (lt)
KR (1) KR20010013709A (lt)
CN (1) CN1260703A (lt)
AP (1) AP1629A (lt)
AR (1) AR012970A1 (lt)
AU (1) AU7831598A (lt)
BG (1) BG103997A (lt)
BR (1) BR9810095A (lt)
CA (1) CA2295176A1 (lt)
CZ (1) CZ298510B6 (lt)
EA (1) EA200000011A1 (lt)
EE (1) EE9900562A (lt)
ES (1) ES2161187B1 (lt)
FI (1) FI19992648A7 (lt)
GB (1) GB2341319B (lt)
HU (1) HUP0003034A2 (lt)
ID (1) ID23516A (lt)
IL (2) IL133396A0 (lt)
IS (1) IS5289A (lt)
LT (1) LT4714B (lt)
LV (1) LV12490B (lt)
NO (1) NO996117L (lt)
NZ (1) NZ501669A (lt)
OA (1) OA11307A (lt)
PL (1) PL196256B1 (lt)
RO (1) RO121252B1 (lt)
SI (1) SI20191A (lt)
SK (1) SK172299A3 (lt)
TN (1) TNSN98086A1 (lt)
TR (1) TR200000540T2 (lt)
WO (1) WO1998056325A1 (lt)
YU (1) YU66099A (lt)
ZA (1) ZA984649B (lt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004255228A1 (en) * 2003-06-30 2005-01-20 Alza Corporation Method for coating skin piercing microprojections
CN1921829B (zh) * 2003-12-05 2010-05-05 纳米比亚医学调查研究有限公司 贴片

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE60941B1 (en) * 1986-07-10 1994-09-07 Elan Transdermal Ltd Transdermal drug delivery device
US4855294A (en) * 1988-09-06 1989-08-08 Theratech, Inc. Method for reducing skin irritation associated with drug/penetration enhancer compositions
US5534260A (en) * 1989-02-23 1996-07-09 University Of Utah Percutaneous drug delivery system
US5028435A (en) * 1989-05-22 1991-07-02 Advanced Polymer Systems, Inc. System and method for transdermal drug delivery
US5624912A (en) * 1991-08-21 1997-04-29 Burcoglu; Arsinur Method of treating HIV infection and related secondary infections with defibrotide
EP0626945B1 (en) * 1992-02-20 1998-04-22 Merrell Pharmaceuticals Inc. Sulfonic acid derivatives in the treatment of viral diseases
IL124733A0 (en) * 1995-12-15 1999-01-26 Cryopreservation Tech Cc Composition for organ cryopreservation and treatment of viral and bacterial infections

Also Published As

Publication number Publication date
YU66099A (sh) 2002-10-18
OA11307A (en) 2003-10-24
RO121252B1 (ro) 2007-02-28
IL133396A (en) 2006-10-05
JP2002511862A (ja) 2002-04-16
LV12490A (en) 2000-06-20
EE9900562A (et) 2000-06-15
BR9810095A (pt) 2001-11-13
LV12490B (en) 2000-12-20
CZ298510B6 (cs) 2007-10-24
KR20010013709A (ko) 2001-02-26
ES2161187B1 (es) 2003-08-16
CZ9904473A3 (cs) 2001-03-14
TR200000540T2 (tr) 2000-09-21
AU7831598A (en) 1998-12-30
FI19992648L (fi) 2000-02-03
FI19992648A7 (fi) 2000-02-03
EA200000011A1 (ru) 2000-08-28
NO996117L (no) 2000-02-11
BG103997A (bg) 2001-07-31
GB2341319A (en) 2000-03-15
NZ501669A (en) 2001-09-28
ZA984649B (en) 1999-12-17
NO996117D0 (no) 1999-12-10
ES2161187A1 (es) 2001-11-16
AR012970A1 (es) 2000-11-22
LT99148A (lt) 2000-07-25
PL196256B1 (pl) 2007-12-31
GB2341319B (en) 2002-02-27
CN1260703A (zh) 2000-07-19
AP1629A (en) 2006-07-11
AP9901708A0 (en) 1999-12-31
HUP0003034A2 (hu) 2000-12-28
JP4531141B2 (ja) 2010-08-25
IS5289A (is) 1999-12-08
LT4714B (lt) 2000-10-25
ID23516A (id) 2000-04-27
EP1011567A4 (en) 2000-06-28
IL133396A0 (en) 2001-04-30
EP1011567A1 (en) 2000-06-28
CA2295176A1 (en) 1998-12-17
SK172299A3 (en) 2000-09-12
GB9929189D0 (en) 2000-02-02
WO1998056325A1 (en) 1998-12-17
PL338439A1 (en) 2000-11-06
TNSN98086A1 (fr) 2005-03-15

Similar Documents

Publication Publication Date Title
US4861759A (en) Antiviral compositions and methods
Broder et al. Antiretroviral therapy in AIDS
Lundgren et al. Antiviral effects of 3′-fluorothymidine and 3′-azidothymidine in cynomolgus monkeys infected with simian immunodeficiency virus
McCracken Jr et al. Cytosine arabinoside in the treatment of congenital cytomegalic inclusion disease
Johnson et al. Synergistic inhibition of human immunodeficiency virus type 1 (HIV-1) replication in vitro by recombinant soluble CD4 and 3′-azido-3′-deoxythymidine
US5935597A (en) Drug delivery devices and methods for treatment of viral and microbial infections and wasting syndromes
Togo et al. Double-blind clinical assessment of ribavirin (virazole) in the prevention of induced infection with type B influenza virus
McKinlay et al. Use of WIN 51711 to prevent echovirus type 9-induced paralysis in suckling mice
MONTEFIORI et al. In vitro evaluation of mismatched double-stranded RNA (ampligen) for combination therapy in the treatment of acquired immunodeficiency syndrome
SI20191A (sl) Priprave za administracijo zdravil ter metode za zdravljenje virusnih in mikrobnih infekcij in sindroma hiranja
EP0183352A2 (en) Use of suramin for clinical treatment of infection with any of the members of the family of human-t-cell leukemia (htvl) viruses including lymphadenopathy virus (lav)
Islam et al. An in‐depth analysis of COVID‐19 treatment: Present situation and prospects
Fischl Combination antiretroviral therapy for HIV infection
JP6644917B2 (ja) エンテロウイルス感染を治療する組成物および薬物併用方法
GB2597635A (en) Combinations
Mathes et al. Evidence that high-dosage zidovudine at time of retrovirus exposure reduces antiviral efficacy
Gupta Therapy of AIDS and AIDS-related syndromes
Zhang et al. Pharmacokinetics of zidovudine in cats
Weber et al. Low-dose zidovudine in combination with either acyclovir or lymphoblastoid interferon-alpha in asymptomatic HIV-infected patients: a pilot study
GUPTA et al. Oxophenarsine, an antisyphilis drug inhibits HIV-1-specific protein synthesis in acutely and persistently infected lymphocytes
Jordan et al. Domestic cat model for predicting human nucleoside analogue pharmacokinetics in blood and seminal plasma
Fritsch et al. Anti-retroviral therapy in HIV-1-infected persons: Concepts and strategies
CA2374198A1 (en) Combination therapy for treatment of fiv infection
Campbell New ant i retro viral agents for the therapy of HIV type-1 infection
Mills et al. Delavirdine